Trial Search Results

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Researchers have found that pembrolizumab can shrink ENKTL when the disease comes back after chemotherapy. The purpose of this study is to test how well pembrolizumab shrinks ENKTL in people who have notyet received chemotherapy. Pembrolizumab is a type of immunotherapy. The goal of immunotherapy is to shatter a protective "shield" that some tumors use to hide from the body's white blood cells (infection fighting cells). The immune system sees these tumors as invasive threats. The tumors are fueled by hundreds of genetic mutations (changes) that stimulates their growth and can be recognized by the immune system. But when white blood cells flood in to attack these cancer cells, they are unable to break through the protective barrier. Immunotherapy drugs can break through the barrier, allowing the immune system to recognize and destroy the tumor cells.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Stanford Investigator(s):

Intervention(s):

  • Drug: Pembrolizumab

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Histologic diagnosis of extranodal NK/T, nasal type cell lymphoma at the enrolling
   institution

   - 18 years of age on day of signing informed consent

   - Have a performance status of ≤ 1 on the ECOG Performance Scale

   - Have measurable disease by PET/CT

   - Demonstrate adequate organ function as defined below:

RENAL:

Serum Creatinine ≤ 1.5 x upper limit of normal (ULN)

OR

Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or
CrCL) Serum creatinine ≥ 60 mL/min for subject with creatinine levels > 1.5 x institutional
ULN ≤ 1.5 x upper limit of normal (ULN)

OR

Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or
CrCL) ≥ 60 mL/min for subject with creatinine levels > 1.5 x institutional ULN

HEPATIC:

Serum total bilirubin ≤ 1.5 x ULN

OR

Serum total bilirubin ≤ 3 x ULN for subjects with liver metastases

AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN

OR

AST (SGOT) and ALT (SGPT) ≤ 5 x ULN for subjects with liver metastases

CARDIAC:

Ejection fraction ≥ 50%

PULMONARY:

Hemoglobin-adjusted diffusing capacity for carbon monoxide ≥ 50%

- Women of childbearing potential* must have a negative urine or serum pregnancy test
(minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to receiving
the first dose of study medication

   - *A woman of childbearing potential is a sexually mature female who has not undergone a
   hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for
   at least 24 consecutive months (i.e. has had menses at any time in the preceding 24
   consecutive months)

      - Women of childbearing potential must be willing to use an adequate method of
      contraception

   - Must agree to practice 2 effective methods of contraception from the time of signing
   the informed consent form through 120 days after the last dose of study therapy, or
   agree to completely abstain from heterosexual intercourse

      - Male subjects of childbearing potential must agree to use an adequate method of
      contraception

   - Male subjects, even if surgically sterilized (i.e. statue post vasectomy) must agree
   to 1 of the following: Practice effective barrier contraception during the entire
   study therapy, or agree to completely abstain from heterosexual intercourse

Exclusion Criteria:

   - Received prior treatment for extranodal NK/T cell lymphoma

   - Medical illness unrelated to lymphoma, which, in the opinion of the treating physician
   and/or institutional principal investigator, makes participation in this study
   inappropriate.

   - Has received a live vaccine within 30 days prior to the first dose of study drug.
   Examples of live vaccines include, but are not limited to, the following: measles,
   mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
   Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
   are generally killed virus vaccines and are allowed; however, intranasal influenza
   vaccines (eg, FluMist) are live attenuated vaccines and are not allowed.

   - Has a known additional malignancy that is progressing or has required active treatment
   within the past 2 years. Note: Participants with basal cell carcinoma of the skin,
   squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma,
   cervical cancer in situ) that have undergone potentially curative therapy are not
   excluded.

   - Has known active CNS metastases and/or carcinomatous meningitis.

   - Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients

   - Has active autoimmune disease that has required systemic treatment in the past 2 years
   (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
   drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid
   replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
   form of systemic treatment.

   - Has a history of (non-infectious) pneumonitis that required steroids or has current
   pneumonitis.

   - Has an active infection requiring systemic therapy.

   - Has a known history of Human Immunodeficiency Virus (HIV).

   - Has active Hepatitis B (defined as HBV DNA is detected) or known active Hepatitis C
   virus (defined as HCV RNA is detected) infection.

   - Has a history or current evidence of any condition, therapy, or laboratory abnormality
   that might confound the results of the study, interfere with the subject's
   participation for the full duration of the study, or is not in the best interest of
   the subject to participate, in the opinion of the treating investigator.

   - Has known psychiatric or substance abuse disorders that would interfere with
   cooperation with the requirements of the trial.

   - Is pregnant or breastfeeding or expecting to conceive or father children within the
   projected duration of the study, starting with the screening visit through 120 days
   after the last dose of trial treatment.

   - Has had an allogenic tissue/solid organ transplant.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Chaitasi Majmudar
650-736-0959
Recruiting